3-(2,3-二氯苯基)丙酸 | 57915-79-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: 3-(2,3-二氯苯基)丙酸
• 英文名称: 3-(2,3-dichlorophenyl)propionic acid
• 英文别名: 3-(2,3-dichlorophenyl)propanoic acid
• CAS: 57915-79-4
• 化学式: C₉H₈Cl₂O₂
• mdl: MFCD06823953
• 分子量: 219.067
• InChiKey: QJOCBCMKVRKWLM-UHFFFAOYSA-N

物化性质

• 熔点：
  117-118 °C
• 沸点：
  339.2±27.0 °C(Predicted)
• 密度：
  1.392±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：室温下干燥密封保存

反应信息

• 作为反应物：
  描述：

  3-(2,3-二氯苯基)丙酸 在 三氯化铝 、 氯化亚砜 、 sodium azide 、 N,N-二甲基甲酰胺 作用下， 以 四氯乙烯 、 水 、 丙酮 、 甲苯 为溶剂， 反应 6.17h， 生成 5,6-dichloro-3,4-dihydro-1(2H)-isoquinolinone
  参考文献：
  名称：

  Inhibitors of phenylethanolamine N-methyltransferase and epinephrine biosynthesis. 1. Chloro-Substituted 1,2,3,4-tetrahydroisoquinolines

  摘要：

  In a search for inhibitors of epinephrine biosynthesis as potential therapeutic agents, a series of 13 ring-chlorinated 1,2,3,4-tetrahydroisoquinolines was prepared. These compounds were tested initially for their ability to inhibit rabbit adrenal phenylethanolamine N-methyltransferase (PNMT) in vitro. Enzyme-inhibitor dissociation constants, determined for the six most potent members of the series, indicated the following order of decreasing potency: 7,8-Cl2 greater than 6,7,8-Cl3 greater than 7-Cl approximately 5,6,7,8-Cl4 greater than 5,7,8-Cl3. These compounds were subsequently examined for PNMT-inhibiting activity in intact rats and mice. 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline (13, SK&F 64139) was the most potent member of the series both in vitro and in vivo and is currently undergoing clinical investigation.

  DOI：

  10.1021/jm00179a007
• 作为产物：
  描述：

  2,3-二氯苯胺 在 sodium hydroxide 、 氢溴酸 、 溶剂黄146 、 copper(I) bromide 、 锌 、 sodium nitrite 作用下， 反应 3.5h， 生成 3-(2,3-二氯苯基)丙酸
  参考文献：
  名称：

  Inhibitors of phenylethanolamine N-methyltransferase and epinephrine biosynthesis. 1. Chloro-Substituted 1,2,3,4-tetrahydroisoquinolines

  摘要：

  In a search for inhibitors of epinephrine biosynthesis as potential therapeutic agents, a series of 13 ring-chlorinated 1,2,3,4-tetrahydroisoquinolines was prepared. These compounds were tested initially for their ability to inhibit rabbit adrenal phenylethanolamine N-methyltransferase (PNMT) in vitro. Enzyme-inhibitor dissociation constants, determined for the six most potent members of the series, indicated the following order of decreasing potency: 7,8-Cl2 greater than 6,7,8-Cl3 greater than 7-Cl approximately 5,6,7,8-Cl4 greater than 5,7,8-Cl3. These compounds were subsequently examined for PNMT-inhibiting activity in intact rats and mice. 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline (13, SK&F 64139) was the most potent member of the series both in vitro and in vivo and is currently undergoing clinical investigation.

  DOI：

  10.1021/jm00179a007

文献信息

• Systematic Variation of Ligand and Cation Parameters Enables Site-Selective C–C and C–N Cross-Coupling of Multiply Chlorinated Arenes through Substrate–Ligand Electrostatic Interactions
  作者：William A. Golding、Hendrik L. Schmitt、Robert J. Phipps

  DOI：10.1021/jacs.0c11056

  日期：2020.12.30

  related sulfonated phosphine ligands and five bases, each possessing varying cation size, to the challenge of site-selective cross-coupling of multiply chlorinated arenes. The fine tuning provided by these ligand/base combinations is effective for Suzuki-Miyaura coupling and Buchwald-Hartwig coupling on a range of isomeric dichlorinated and trichlorinated arenes, substrates that would produce intractable

  使用配体和底物之间有吸引力的非共价相互作用是控制位置选择性的新兴策略。一个关键问题涉及是否可以使用通常较少定向的静电相互作用来实现对具有多个紧密间隔的反应位置的分子的精细控制。在这里，我们应用了一个由两个密切相关的磺化膦配体和五个碱基组成的 10 件“工具包”，每个碱基都具有不同的阳离子大小，以应对多氯化芳烃的位点选择性交叉偶联的挑战。这些配体/碱基组合提供的微调对于 Suzuki-Miyaura 偶联和 Buchwald-Hartwig 偶联对一系列异构二氯化和三氯化芳烃是有效的，这些底物在使用典型配体时会产生难以处理的混合物。
• NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE
  申请人：Okano Akihiro

  公开号：US20120220772A1

  公开（公告）日：2012-08-30

  [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is a specific cyclic group; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is —CH 2 —, O, —S(O) i — (i is 0 to 2), or —NR 7 —; R 1 to R 6 are specific groups), a salt of the compound, or a solvate of the salt or the compound.

  提供一种GPR40激活剂，其作为活性成分具有一种具有GPR40激动剂作用的新化合物，该化合物的盐、盐或化合物的溶剂或类似物，特别是一种胰岛素分泌促进剂以及预防和/或治疗糖尿病、肥胖或其他疾病的药物。 通过以下公式(I)的化合物解决问题： （其中p为0至4；j为0至3；k为0至2；环A为特定的环状基团；环B为苯环、吡啶环或嘧啶环；X为—CH2—、O、—S(O)i—（i为0至2）或—NR7—；R1至R6为特定的基团），该化合物的盐或盐的溶剂。
• 4 AND 5-Halo substituted 2-indanamine compounds
  申请人：SmithKline Corporation

  公开号：US04128666A1

  公开（公告）日：1978-12-05

  2-Indanamine compounds having 4 and 5-halo substituents are inhibitors of phenylethanolamine N-methyltransferase.

  2-Indanamine化合物具有4和5位卤素取代基，可以抑制苯乙醇胺N-甲基转移酶。
• Benzodiazepine derivatives as inhibitors of gamma secretase
  申请人：——

  公开号：US20040024203A1

  公开（公告）日：2004-02-05

  Compounds of formula (I) are disclosed. The compounds inhibit the action of gamma secretase, and hence find use in the treatment and prevention of Alzheimer's disease.

  公式（I）的化合物被披露。这些化合物抑制γ-分泌酶的作用，因此可用于治疗和预防阿尔茨海默病。
• Ligands of melanocortin receptors and compositions and methods related thereto
  申请人：Tucci C. Fabio

  公开号：US20050119252A1

  公开（公告）日：2005-06-02

  Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders. The compounds have the following structure (I): including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein m, n, q, s, R 1 , R 1a , R 1b , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b , X 1 , X 2 , X 3 , X 4 and Ar are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.

  这是一种功能为黑素皮质素受体配体的化合物，可用于治疗基于黑素皮质素受体的疾病。该化合物具有以下结构（I）：包括立体异构体，前药和其药学上可接受的盐，其中m，n，q，s，R1，R1a，R1b，R2，R3，R4a，R4b，R5a，R5b，X1，X2，X3，X4和Ar的定义如本文所述。还公开了含有结构（I）化合物的药物组成物，以及与其使用相关的方法。